Gene therapy trial hopes to restore dopamine in young Parkinson's patients
Disease control
Not yet recruiting
This early-stage study tests whether a gene therapy called AAV2-hAADC is safe for people with young onset Parkinson's disease. The therapy delivers a gene into two brain areas to help convert levodopa into dopamine, the chemical that is lacking in Parkinson's. Nine participants a…
Phase: PHASE1 • Sponsor: Krzysztof Bankiewicz • Aim: Disease control
Last updated Jun 08, 2026 13:04 UTC